LY2880070
LY2880070 is an orally active CHK1 inhibitor, IC50 [1][2].
Product Specifications
CAS Number
[1375637-35-6]
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Checkpoint Kinase (Chk)
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ly2880070.html
Purity
99.77
Solubility
DMSO : 160 mg/mL (ultrasonic)
Smiles
COC1=C(C=CC(C)=N1)C2=CC(NC3=NC(O[C@@H]4CCCNC4)=CN=C3)=NN2
Molecular Formula
C19H23N7O2
Molecular Weight
381.43
Precautions
H315, H319, H335
References & Citations
[1]Quincy S, et al. A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 2020 38:15_suppl, 3581.|[2]Kailong Jiang, et al. Functions and inhibitors of CHK1 in cancer therapy. Medicine in Drug Discovery. Volume 22, June 2024, 100185.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
243699-ML405 100 µL
BACE1 (beta-site APP-cleaving Enzyme 1, ASP2, BACE, FLJ90568, HSPC104, KIAA1149) (MaxLight 405) discontinued
Ask
View Details 
